Regeneron Pharmaceuticals (REGN) Projected to Post Earnings on Tuesday

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, April 29th. Analysts expect Regeneron Pharmaceuticals to post earnings of $8.83 per share and revenue of $3.40 billion for the quarter.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals's revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $11.86 earnings per share. On average, analysts expect Regeneron Pharmaceuticals to post $36 EPS for the current fiscal year and $38 EPS for the next fiscal year.

Regeneron Pharmaceuticals Stock Up 0.5 %

NASDAQ REGN traded up $2.88 on Friday, hitting $602.64. 964,377 shares of the company were exchanged, compared to its average volume of 724,654. The company has a market cap of $65.88 billion, a PE ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. Regeneron Pharmaceuticals has a 12 month low of $525.99 and a 12 month high of $1,211.20. The stock has a fifty day moving average of $637.38 and a 200-day moving average of $721.91. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.58%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

An institutional investor recently raised its position in Regeneron Pharmaceuticals stock. Brighton Jones LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 261.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 948 shares of the biopharmaceutical company's stock after acquiring an additional 686 shares during the quarter. Brighton Jones LLC's holdings in Regeneron Pharmaceuticals were worth $675,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating on the stock in a report on Monday, March 31st. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. The Goldman Sachs Group lowered their price objective on shares of Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a "buy" rating on the stock in a report on Monday, April 14th. Finally, UBS Group downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $945.32.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.